Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on healthrelated quality of life

Authors Marc Miravitlles, Carles Llor, Jesús Molina, et al

Published Date January 2010 Volume 2010:5 Pages 11—19

DOI http://dx.doi.org/10.2147/COPD.S8732

Published 15 January 2010

Marc Miravitlles1, Carles Llor2, Jesús Molina3, Karlos Naberan4, Josep M Cots5, Fernando Ros6 on behalf of the EVOCA Study Group

1Fundació Clínic. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Primary Health Care Center ‘Jaume I’, Societat Catalana de Medicina Familiar i Comunitària, Universitat Rovira i Virgili, Tarragona, Spain; 3Primary Health Care Center ‘Francia’, Grupo de Respiratorio de la Sociedad Madrileña de Medicina Familiar y Comunitaria, Madrid, Spain; 4Primary Health Care Center ‘Fuentes de Ebro’, Grupo de Investigación del Instituto Aragonés Ciencias de la Salud (IACS), Zaragoza, Spain; 5Primary Health Care Center ‘La Marina’, Societat Catalana de Medicina Familiar i Comunitària, Facultat de Medicina, Barcelona, Spain; 6Medical Department, Bayer Healthcare, Barcelona, Spain

Objective: To investigate the impact of exacerbations in health-related quality of life (HRQL) of patients with COPD and to compare the effect of treatment of COPD exacerbations with moxifloxacin (400 mg/day for 5 days) and amoxicillin/clavulanate (500/125 mg 3 times a day for 10 days) on HRQL.

Methods: 229 outpatients with stable COPD (mean age 68.2 years; mean FEV1 % predicted 49.3%) participated in a prospective, observational study of 2 years’ duration. The St George’s Respiratory Questionnaire (SGRQ) was completed at baseline and every 6 months thereafter.

Results: COPD exacerbations (mean 2.7 episodes/patient) occurred in 136 patients (124 patients received the study medications [amoxicillin/clavulanate 54, moxifloxacin 70]). Differences between baseline and the final visit were higher for moxifloxacin compared with amoxicillin/clavulanate for total SGRQ score (-2.60 [13.1] vs 4.21 [16.2], P = 0.05) and “Symptoms” subscale (-5.64 [16.7] vs 8.27 [21], P = 0.02). The same findings were observed in patients with two or more exacerbations.

Conclusions: In COPD outpatients, treatment of exacerbations with moxifloxacin had a more favorable long-term effect on quality of life than amoxicillin/clavulanate.
Keywords: COPD, exacerbations, moxifloxacin, amoxicillin/clavulanate, quality of life, SGRQ

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 15 September 2008

Readers of this article also read:

A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting

Wang SM, He X, Li N, Yu F, Hu Y, Wang LS, Zhang P, Du YK, Du SS, Yin ZF, Wei YR, Mulet X, Coia G, Weng D, He JH, Wu M, Li HP

International Journal of Nanomedicine 2015, 10:2857-2869

Published Date: 13 April 2015

Binding of plasma proteins to titanium dioxide nanotubes with different diameters

Kulkarni M, Flašker A, Lokar M, Mrak-Poljšak K, Mazare A, Artenjak A, Čučnik S, Kralj S, Velikonja A, Schmuki P, Kralj-Iglič V, Sodin-Semrl S, Iglič A

International Journal of Nanomedicine 2015, 10:1359-1373

Published Date: 18 February 2015

Drug therapies and presence of coronary artery disease may affect aortic stiffness in Alzheimer’s disease

Bektaş O, Günaydın ZY, Karagöz A, Kaya A

Clinical Interventions in Aging 2015, 10:469-471

Published Date: 13 February 2015

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies

Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX

International Journal of Nanomedicine 2015, 10:633-644

Published Date: 14 January 2015

Molecular photoacoustic imaging of breast cancer using an actively targeted conjugated polymer

Balasundaram G, Ho CJH, Li K, Driessen WH, Dinish US, Wong CL, Ntziachristos V, Liu B, Olivo M

International Journal of Nanomedicine 2015, 10:387-397

Published Date: 8 January 2015

Altered diastolic function and aortic stiffness in Alzheimer’s disease

Çalık AN, Özcan KS, Yüksel G, Güngör B, Aruğarslan E, Varlibas F, Ekmekci A, Osmonov D, Tatlısu MA, Karaca M, Bolca O, Erdinler I

Clinical Interventions in Aging 2014, 9:1115-1121

Published Date: 16 July 2014

Differential effects of nanoselenium doping on healthy and cancerous osteoblasts in coculture on titanium

Phong A Tran, Love Sarin, Robert H Hurt, et al

International Journal of Nanomedicine 2010, 5:351-358

Published Date: 10 May 2010